Table 4.
Impacts of clinicopathologic parameters on RFS in 58 APL patients during maintenance therapy
| Clinicopathologic parameters | 3-year RFS | P-value (log-rank) |
|---|---|---|
| Sex | 0.4376 | |
| Male | 0.8640 | |
| Female | 0.9630 | |
| Age (years) | 0.8146 | |
| ≤40 | 0.8889 | |
| >40 | 0.9305 | |
| WBC count (×109/L) | 0.6536 | |
| ≤5 | 0.9128 | |
| >5 | 0.9000 | |
| Platelet count (×109/L) | 0.3020 | |
| ≤40 | 0.8733 | |
| >40 | 1.0000 | |
| Hemoglobin (g/L) | 0.0895 | |
| <100 | 0.9491 | |
| ≥100 | 0.8125 | |
| Induction regimens | 0.2724 | |
| ATRA+As2O3+IDA | 1.0000 | |
| ATRA+IDA | 0.8908 | |
| Maintenance regimens | 0.0159 | |
| ATRA+As2O3 | 1.0000 | |
| ATRA+chemotherapy | 0.8182 |
Abbreviations: APL, acute promyelocytic leukemia; As2O3, arsenic trioxide; ATRA, all-trans retinoic acid; IDA, idarubicin; RFS, relapse-free survival; WBC, white blood cell.